Guillausseau C, Eyquem A, Vincens M, Laurent M F, Leger A F, Savoie J C
Pathol Biol (Paris). 1985 Jun;33(6):653-8.
Antithyroid microsomal hemagglutination antibody (MCHA) and antithyroglobulin hemagglutination antibody (TGHA) were measured in 629 patients with thyroid disease and 100 controls. Thyroid antibodies were present in 4% of control patients, only in women and at low titer. Thyroid antibodies prevalence was 97% in autoimmune thyroiditis (MCHA: 93%; TGHA: 53%), was 55% in Graves disease before treatment (MCHA: 46%; TGHA: 33%) and 90% in the first year following 131I therapy. Antibodies prevalence was 57% in myxoedema (MCHA: 52%; TGHA: 25%). In patients with iodine overload, antibodies prevalence was 29% in euthyroid patients, 25% in iodine-induced hyperthyroidism and 55% in iodine-induced hypothyroidism. Thyroid antibodies detection should be systematically performed in the routine evaluation of any thyroid disorder. Because of discrepancies between TGHA and MCHA positivity, their simultaneous detection should be performed.
对629例甲状腺疾病患者和100例对照者检测了抗甲状腺微粒体血凝抗体(MCHA)和抗甲状腺球蛋白血凝抗体(TGHA)。对照患者中4%存在甲状腺抗体,仅见于女性且滴度较低。自身免疫性甲状腺炎中甲状腺抗体患病率为97%(MCHA:93%;TGHA:53%),治疗前格雷夫斯病中为55%(MCHA:46%;TGHA:33%),131I治疗后第一年为90%。黏液性水肿中抗体患病率为57%(MCHA:52%;TGHA:25%)。在碘负荷过量患者中,甲状腺功能正常者抗体患病率为29%,碘致甲状腺功能亢进症中为25%,碘致甲状腺功能减退症中为55%。在任何甲状腺疾病的常规评估中均应系统检测甲状腺抗体。由于TGHA和MCHA阳性情况存在差异,应同时检测二者。